Table 2.

Responses to treatment at 12 months after kidney biopsy in SLE patients with aPLN. Values are median (IQR) or mean ± SD.

Treatment ResponsesNon-RASI, n = 17RASI, n = 40p
eGFR, ml/min/1.73m289 (68–98)90 (62–102)0.800
  Improvement ratio, %−2 (−20 to 20)26 (−5 to 86)0.028
MAP, mmHg89 ± 8; 90 (67–100)94 ± 11; 93 (77–123)0.130
  Improvement ratio, %8 ± 16; 0 (−7 to 17)12 ± 18; 14 (0–25)0.508
Proteinuria level, g/d0.3 (0.1–0.9)0.4 (0–0.9)0.403
  Improvement ratio, %90 (55–95)90 (81–96)0.457
  • Data in bold face are statistically significant. SLE: systemic lupus erythematosus; aPLN: antiphospholipid-associated nephropathy; IQR: interquartile range; RASI: renin-angiotensin system inhibitor; eGFR: estimated glomerular filtration rate; MAP: mean arterial blood pressure.